CRISPR Therapeutics AG (CRSP)

116.43
NASDAQ
Prev Close 121.25
Day Low/High 116.01 / 120.24
52 Wk Low/High 79.31 / 220.20
Exchange NASDAQ
Shares Outstanding 76.20B
Market Cap 9.24B
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

CRISPR Therapeutics Could Suffer Further Steep Losses

CRISPR Therapeutics Could Suffer Further Steep Losses

Let's look over the charts and indicators.

Here Are Sectors and Themes Promoted in Social Media

Here Are Sectors and Themes Promoted in Social Media

What's most important about this market is understanding which themes are driving the action.

CRISPR Therapeutics Has Soared in Just a Few Weeks - What to Do Now

CRISPR Therapeutics Has Soared in Just a Few Weeks - What to Do Now

This is a time to nail down profits.

CRISPR Therapeutics Is Still Looking Strong

CRISPR Therapeutics Is Still Looking Strong

We've arrived at new price targets for the shares.

Cutting Edge CRISPR Therapeutics Has Cut a Path Higher

Cutting Edge CRISPR Therapeutics Has Cut a Path Higher

Let's review the charts and indicators.

Crispr Therapeutics Gets an Upgrade but Needs Help on the Charts

Crispr Therapeutics Gets an Upgrade but Needs Help on the Charts

The shares have been correcting since July.

CRISPR Therapeutics Stock Shows It Has Good Genes

CRISPR Therapeutics Stock Shows It Has Good Genes

These shares have some bullish charts.

4 ETFs on the Cutting Edge: Data, Genomics, Robotics and Fintech

4 ETFs on the Cutting Edge: Data, Genomics, Robotics and Fintech

These ARK Funds family funds are focused on new opportunities and investment themes.

These Intriguing ETFs Are on the Cutting Edge of Disruptive Technologies

These Intriguing ETFs Are on the Cutting Edge of Disruptive Technologies

Ark Invest has developed a series of specialized exchange-traded funds that own shares in companies involved in 'disruptive innovation.'

Illumina Could Rally to Break Its Downtrend

Illumina Could Rally to Break Its Downtrend

Here's how we would play ILMN stock right now.

Intellia Therapeutics Has Upside in Its DNA

Intellia Therapeutics Has Upside in Its DNA

The setup here is appealing enough to take a small, aggressive shot on the long side.

The Confidence in the Dip Buyers Has Weakened

The Confidence in the Dip Buyers Has Weakened

The bears are likely to be increasingly bold if there's a failed bounce.